TL;DR
This paper presents a complementary approach to drug discovery by combining X-ray crystallography and mass spectrometry to study aldose reductase inhibitors. They demonstrate that gas-phase stability measurements from mass spectrometry can rapidly assess the electrostatic and hydrogen-bonding interactions of inhibitors with the enzyme, offering a valuable tool for monitoring drug design optimization.
What Problem Does This Paper Address?
Diabetes mellitus is associated with severe degenerative complications, and aldose reductase (AR) is implicated in these issues. Developing specific AR inhibitors is a major pharmaceutical goal. While X-ray crystallography provides detailed structural insights into how inhibitors bind to AR, it's a time-consuming process, making it unsuitable for high-throughput screening of numerous potential drug candidates. The challenge is to find a faster method to evaluate inhibitor binding, particularly focusing on key interactions that can be readily modified during drug design, without sacrificing accuracy.
Methods
The study employs two primary techniques:
- X-ray Crystallography: This method was used to determine the precise atomic-level interactions between aldose reductase and four different inhibitors (AminoSNM, Imirestat, LCB3071, and IDD384). This provided detailed information about the contacts, including hydrogen bonds and electrostatic interactions, within the enzyme's active site.
- Electrospray Ionization Mass Spectrometry (ESI-MS): This technique was used to measure the gas-phase stability of noncovalent enzyme-coenzyme-inhibitor complexes. By increasing the accelerating voltage (Vc) in the mass spectrometer's interface region, the researchers induced dissociation of these complexes. The voltage required to dissociate 50% of the complex (Vc50) served as a measure of its gas-phase stability. This method is significantly faster than crystallography.
Datasets
The study used four specific aldose reductase inhibitors: AminoSNM, Imirestat, LCB3071, and IDD384. These inhibitors represent different structural classes and were chosen for their relevance to drug development. The aldose reductase enzyme used was from pig lens and also a recombinant human form, with both showing similar behavior in ESI-MS.
Key Insights and Ideas
- Mass Spectrometry as a Rapid Screening Tool: The core idea is that gas-phase stability (measured by Vc50) can serve as a proxy for the strength of electrostatic and hydrogen-bonding interactions, which are crucial and readily modifiable during drug design. This allows for rapid screening of many potential inhibitors.
- Correlation Between Gas-Phase Stability and Electrostatic/H-bond Interactions: The study found a strong correlation between the Vc50 values (gas-phase stability) and the calculated electrostatic and hydrogen-bond binding energies (Eel-H) derived from crystallographic data. This validates the hypothesis that gas-phase stability is largely dictated by these specific interactions.
- Discrepancy Between Gas-Phase and Solution-Phase Binding: Importantly, the gas-phase stability (Vc50) did not directly correlate with the solution-phase inhibition constants (IC50). This highlights that hydrophobic interactions, which contribute significantly to solution-phase binding but are likely lost in the gas phase, play a different role in each measurement.
- Complementary Nature of Techniques: The paper strongly advocates for using X-ray crystallography and mass spectrometry in tandem. Crystallography provides the detailed "why" and "how," while mass spectrometry offers a rapid "how much" for specific interaction types, guiding the optimization process.
Key Results
- Vc50 Values and Stability Ranking: The inhibitors were ranked by gas-phase stability (highest to lowest) as: IDD384 > LCB3071 > Imirestat > AminoSNM. This ranking was consistent with the calculated electrostatic and H-bond binding energies.
- Correlation Strength: A clear correlation was observed between the calculated Eel-H and the measured VC50 values, supporting the idea that gas-phase stability reflects these specific interactions.
- Lack of Correlation with IC50: The order of inhibitors based on solution-phase inhibition (IC50) was significantly different from the gas-phase stability order, emphasizing the distinct contributions of hydrophobic forces in solution. For example, IDD384, with a poor hydrophobic interaction, showed high gas-phase stability but lower solution-phase potency compared to LCB3071.
Limitations and Future Work
- Protein Conformation in Gas Phase: A key limitation acknowledged is that the protein's 3D structure might be altered in the gas phase compared to its solution state. This could affect the active site geometry and thus the measured binding energies. The authors suggest that preliminary verification of structural integrity in the gas phase is necessary for other protein-ligand systems.
- Hydrophobic Interactions: The study focuses on electrostatic and H-bond interactions, assuming hydrophobic contributions are lost in the gas phase. While this is a strength for monitoring specific modifications, it means gas-phase stability alone cannot fully predict solution-phase binding affinity.
- Future Work: The authors propose using this complementary approach for drug design optimization. They suggest an iterative process: initial IC50 screening to identify promising candidates, followed by ESI-MS to monitor chemical modifications that enhance electrostatic/H-bond interactions, and finally, X-ray crystallography for detailed structural rationalization. Further studies are needed to confirm these findings across a broader range of protein-ligand systems.
Summary updated